Approval · Notice of Compliance 5367 · 1994

LAMICTAL: Notice of Compliance 5367

Issued November 21, 1994

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 5367
Date: November 21, 1994
Company: Glaxo Wellcome Inc.Mississauga, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)
Therapeutic class: Anti-epileptic

Products in this notice

Brand	DIN	Status today
LAMICTAL	02142082	Marketed
LAMICTAL	02142090	—
LAMICTAL	02142104	Marketed
LAMICTAL	02142112	Marketed
LAMICTAL	02142120	Cancelled Post Market
LAMICTAL	02142139	—

Medicinal ingredients

LAMOTRIGINE 25 MG per TAB
LAMOTRIGINE 50 MG per TAB
LAMOTRIGINE 100 MG per TAB
LAMOTRIGINE 150 MG per TAB
LAMOTRIGINE 200 MG per TAB
LAMOTRIGINE 250 MG per TAB